Trial Profile

A Study Evaluated the Safety and Efficacy of BAT6026 in Patients with Moderate to Severe Atopic Dermatitis Phase I/II Clinical Study

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 6026 (Primary)
Indications Atopic dermatitis
Focus Adverse reactions
Sponsors Bio-Thera Solutions

Most Recent Events

18 Nov 2024 Planned number of patients changed from 126 to 33.
01 Feb 2024 According to an Bio-Thera Solutions media release, dosing has begun in this trial.
17 Jan 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com